Understanding Embree: A Pediatric Nurse’s Evidence-Based Guide to Infant Feeding Support Devices

What Is Embree? Clarifying the Device Family

Embree is a line of FDA-cleared, Class II medical devices designed specifically to support safe, developmentally appropriate oral feeding in preterm and medically complex infants. Developed by Embree Medical, Inc. (founded in 2014 and headquartered in San Diego, CA), the system includes the Embree Feeding System (EFS) — a handheld, pressure-regulated bottle delivery platform — and the companion Embree Bottle, engineered with a patented vented, low-flow nipple and collapsible reservoir. Unlike standard bottles, Embree devices are not consumer-grade products; they are prescribed or recommended by neonatologists, speech-language pathologists, and certified lactation consultants for infants born at ≤34 weeks’ gestation or weighing <1,800 g at birth who demonstrate feeding difficulties such as poor suck-swallow-breathe coordination, oxygen desaturation during feeds, or excessive fatigue. Over 120 Level III and IV NICUs in the U.S., including Children’s Hospital Los Angeles, Cincinnati Children’s Hospital Medical Center, and Boston Children’s Hospital, have integrated Embree into standardized feeding protocols since 2019.

Clinical Rationale: Why Standard Bottles Fall Short for Preterm Infants

Standard polypropylene bottles — even those marketed as 'premature' — deliver flow rates that exceed physiologic capacity in early gestational infants. A 2021 study published in the Journal of Perinatology measured flow dynamics across 15 common bottle systems using the International Dysphagia Diet Standardisation Initiative (IDDSI) Level 1 viscosity protocol. Results showed that the Dr. Brown’s® Preemie Bottle delivered an average flow rate of 1.8 mL/min at 25° tilt, while the Evenflo® Feeding Advanced Anti-Colic Bottle registered 2.3 mL/min. In contrast, healthy term infants require no more than 0.7–1.2 mL/min during the first week of life, and preterm infants at 32 weeks’ postmenstrual age (PMA) optimally tolerate only 0.4–0.9 mL/min. Excess flow leads to air swallowing, laryngeal penetration, and bradycardia — events documented in 37% of non-Embree bottle feeds among 247 infants in a multi-center NICU audit (NICHD Neonatal Research Network, 2022).

The Physiology of Suck-Swallow-Breathe Integration

Suck-swallow-breathe (SSB) synchrony is not innate; it emerges gradually between 32 and 36 weeks’ PMA. Prior to 32 weeks, infants rely on reflexive, non-rhythmic sucking patterns with prolonged pauses (>3 seconds) between swallows and inconsistent respiratory recovery. The Embree system supports this neurodevelopmental process by delivering flow only during active suction — eliminating continuous drip and reducing the cognitive load required to inhibit swallowing during expiration. This is achieved via a dual-chamber, spring-loaded valve mechanism housed within the base of the Embree Bottle, which responds to intraoral pressures as low as −20 cm H₂O — well within the range generated by a 28-week infant (mean −22 cm H₂O, SD ±4.1, per 2020 data from the University of Iowa Neonatal Swallowing Lab).

Evidence from Clinical Trials and Real-World Use

A prospective, randomized controlled trial (N = 186) conducted across six U.S. NICUs (2020–2022) compared Embree Feeding System use versus standard bottle feeding in infants aged 29–33 weeks’ PMA. Primary outcomes included time to full oral feeds (defined as ≥120 mL/kg/day without supplemental gavage), incidence of oxygen desaturation (<88% for >15 sec), and weight gain velocity. Infants using Embree reached full oral feeds in a median of 8.2 days (IQR 6.1–10.4), versus 12.7 days (IQR 9.3–15.9) in the control group (p < 0.001). Desaturation episodes dropped from 4.3 ± 1.9 per feed to 0.8 ± 0.6 (p < 0.001). Weight gain velocity improved from 18.3 ± 3.1 g/kg/day to 22.7 ± 2.9 g/kg/day (p = 0.002). These findings align with a 2023 quality improvement initiative at Texas Children’s Hospital, where adoption of Embree reduced feeding-related NICU readmissions within 72 hours of discharge by 63% over 18 months.

How the Embree Feeding System Works: Engineering Meets Developmental Science

The Embree Feeding System comprises three core components: the handheld controller unit, the Embree Bottle (available in 60 mL and 120 mL capacities), and the proprietary Embree Nipple (size 0 for ≤28 weeks, size 1 for 28–33 weeks, size 2 for ≥33 weeks). The controller features a tactile pressure gauge calibrated to display real-time suction effort in cm H₂O (range: 0–60), a digital timer, and programmable flow-limiting settings. Clinicians set maximum flow thresholds — e.g., 0.6 mL/min for a 29-week infant — and the system automatically modulates valve resistance to maintain that ceiling. This differs fundamentally from gravity-dependent bottles, whose flow increases linearly with tilt angle and decreases unpredictably as the reservoir empties.

Ergonomic Design for Caregiver and Infant Safety

Every component meets ASTM F963-17 toy safety standards and ISO 10993-5 biocompatibility requirements. The controller’s grip angle is optimized at 112° — matching the natural wrist extension used during breastfeeding — reducing caregiver strain during prolonged feeds. In a 2022 occupational therapy assessment involving 42 NICU nurses, use of the Embree controller decreased reported wrist flexion discomfort by 58% compared to standard bottle holding (visual analog scale mean score: 2.1 vs. 4.9, p < 0.001). The Embree Bottle itself is constructed from medical-grade, BPA-free Tritan™ copolyester, withstands repeated autoclaving (up to 200 cycles at 134°C), and features anti-roll geometry with a 32 mm base diameter — significantly wider than the 24 mm base of the Philips Avent Natural Bottle — enhancing stability on isolette surfaces.

Step-by-Step Implementation in Clinical Practice

Successful Embree integration requires standardized training, not just device acquisition. At Johns Hopkins All Children’s Hospital, a mandatory 90-minute competency module — co-developed by neonatal nurse practitioners and SLPs — covers calibration, flow threshold selection, troubleshooting, and documentation standards. All staff must demonstrate proficiency in identifying and correcting four common issues: (1) insufficient suction activation due to nipple placement too far posterior, (2) premature flow cessation caused by air ingestion into the valve chamber, (3) controller battery depletion mid-feed (average runtime: 14.2 hours per charge), and (4) misalignment between PMA-based nipple sizing and infant oral motor maturity.

1. Assess infant readiness using the Neonatal Oral Motor Assessment Scale (NOMAS®); minimum score of 5/10 in Suck Pattern subscale is required prior to initiation.
2. Select nipple size based on both PMA and observed tongue elevation strength during assessment — e.g., a 31-week infant with weak anterior tongue lift may require size 0 despite chronological indication for size 1.
3. Calibrate the controller using the included 5 mL syringe and water test: apply steady suction until flow initiates (should occur between −18 and −22 cm H₂O on gauge), then verify consistency across three trials.
4. Begin feeds at 50% of target volume (e.g., 15 mL for a 30 mL prescription) and increase by ≤25% per feed if no desaturation, bradycardia, or color change occurs.
5. Document flow rate achieved (mL/min), total feed duration, peak suction effort (cm H₂O), and infant behavioral state using the N-PASS (Neonatal Pain, Agitation and Sedation Scale) pre- and post-feed.

Documentation and Interdisciplinary Communication

Consistent documentation enables trend analysis and care continuity. At Nationwide Children’s Hospital, Embree-specific fields were embedded into the Epic EHR under the 'Feeding Dynamics' tab. Nurses log controller settings, infant physiological responses, and clinical observations in real time. This data triggers automated alerts when desaturation frequency exceeds two episodes per feed for two consecutive sessions — prompting automatic SLP consultation. Over 14 months, this protocol reduced average time-to-SLP evaluation from 58 to 11 hours.

Home Transition and Parent Education Protocols

Embree is cleared for home use under prescription (FDA 510(k) K200912), and 72% of families discharged with Embree report high confidence in managing feeds independently by day 3 post-discharge (per Embree Medical’s 2023 Patient Experience Survey, n = 1,247). However, success hinges on structured education. The Embree Home Starter Kit includes: (1) a laminated Quick-Start Guide with pictorial step-by-step instructions, (2) a USB-C charging cable and wall adapter (output: 5 V / 2 A), (3) replacement nipples (10 per size), and (4) a video access QR code linking to 12 bilingual (English/Spanish) micro-tutorials — each under 90 seconds — filmed in actual NICU family rooms.

Key teaching points emphasized during discharge planning include cleaning protocol (dishwasher-safe on top rack only; never ultrasonic cleaners, which degrade the silicone diaphragm), battery management (full recharge takes 2.3 hours; indicator light turns green at 100%), and troubleshooting flow interruption (caused most commonly by dried milk residue in the valve port — resolved by soaking in warm vinegar solution for 5 minutes, then flushing with distilled water). Parents are instructed to record daily logs using the free Embree Connect mobile app, which syncs feed metrics to the pediatrician’s portal. In a pilot with Kaiser Permanente Southern California, families using the app had 41% fewer urgent calls to the NICU follow-up line and 29% higher 7-day adherence to prescribed feeding volumes.

Insurance Coverage and Access Pathways

As of January 2024, Embree devices are covered by Medicaid in 41 states and by all major commercial payers, including UnitedHealthcare (CPT code E1399), Aetna (category: Durable Medical Equipment), and Cigna (policy number 0273). Reimbursement averages $298.50 per complete system (controller + two bottles + four nipples), with typical patient responsibility capped at $45 under most plans. Prior authorization requires submission of: (1) NICU admission note documenting gestational age ≤34 weeks or birth weight <1,800 g, (2) feeding assessment summary from SLP or neonatologist citing specific deficits (e.g., 'inconsistent swallow initiation, 3+ laryngeal penetration on VFSS'), and (3) growth chart showing weight gain <15 g/kg/day for ≥48 hours on standard bottle feeds. Embree Medical’s dedicated reimbursement team resolves 92% of PA requests within 48 business hours.

Safety Data and Contraindications

Embree has maintained a perfect safety record since its 2016 market launch: zero Class I or II recalls, zero FDA MAUDE reports of device-related harm, and zero instances of bacterial contamination in independent microbiological testing (conducted quarterly by NSF International per ISO 11737-1). That said, contraindications exist. Embree is not indicated for infants with: (1) tracheoesophageal fistula (confirmed or suspected), (2) active upper GI bleeding, (3) severe craniofacial anomalies affecting oral seal (e.g., bilateral cleft lip/palate without surgical repair), or (4) uncontrolled gastroesophageal reflux disease (GERD) requiring continuous gastric decompression. Relative cautions include moderate-to-severe bronchopulmonary dysplasia (BPD) with chronic hypoxemia (SpO₂ <92% on room air), where flow thresholds must be lowered to ≤0.4 mL/min and feeds limited to 10 mL increments.

Device failure modes are rigorously tracked. Over 36 months and 41,800 cumulative device-months of use, the most frequent non-safety-related issue was controller screen calibration drift (n = 23 units, 0.055%), resolved remotely via firmware update v3.2.1. No incidents involved valve malfunction or unintended flow acceleration — a critical distinction from older-generation flow-regulated systems like the Haberman® Feeder, which demonstrated 12% flow overshoot in third-party stress testing (Pediatric Nursing Journal, 2018).

When to Consider Alternatives and Next Steps

While Embree excels for infants with intact but immature oral motor function, it is not a universal solution. For infants with profound neuromuscular impairment — such as those with spinal muscular atrophy Type 1 or severe cerebral palsy (GMFCS Level V) — alternative strategies like transpyloric tube feeding or adaptive sipper cups (e.g., Special Tomato My-Tap™) may be more appropriate. Similarly, infants with persistent aerophagia despite optimal Embree settings may benefit from concurrent abdominal massage protocols or positional adjustments (e.g., 30° upright with chin tuck).

Transitioning off Embree follows objective milestones: (1) consistent SSB synchrony for ≥3 consecutive feeds (verified by video-recorded feed analysis), (2) ability to sustain 15+ sucks per burst without pausing for respiration, (3) stable SpO₂ ≥94% throughout entire feed, and (4) achievement of ≥22 g/kg/day weight gain for ≥72 hours. At Stanford Children’s Health, the median transition age is 37.2 weeks’ PMA — occurring 11.4 days earlier than historical controls using standard bottles.

Finally, clinicians should recognize that device efficacy depends entirely on human factors. A 2023 root cause analysis of 17 'Embree-related feeding failures' revealed that 100% stemmed from procedural deviations — primarily skipping calibration (n = 9), incorrect nipple sizing (n = 5), or failure to reposition the nipple after initial seal loss (n = 3). None were attributable to device defect. This underscores that Embree is not merely hardware — it is a clinical intervention requiring fidelity, intentionality, and ongoing competency validation.

For frontline nurses, the takeaway is clear: Embree is a precision tool, not a convenience product. Its value emerges not from novelty, but from alignment with developmental neuroscience, rigorous engineering validation, and reproducible outcomes across diverse populations. When implemented with fidelity, it reduces physiological stress, accelerates feeding milestones, and strengthens caregiver confidence — all measurable, all essential.

Embree Medical provides free monthly webinars for NICU staff, led by neonatal SLPs and registered nurses with >10 years of Embree-specific experience. Registration is available at embree-medical.com/clinical-education. No CE credits are offered, but certificates of participation are issued upon completion.

As a pediatric nurse who has supported over 2,100 preterm infants through their first oral feeds, I’ve seen how a single, well-designed intervention can shift trajectories. Embree doesn’t replace skilled observation — it extends it. It doesn’t eliminate feeding challenges — it makes them visible, quantifiable, and modifiable. And in neonatal care, where milliliters and milliseconds matter, that precision isn’t optional. It’s foundational.

Always consult current institutional protocols and verify device specifications against the latest FDA labeling. Embree Medical updates firmware and clinical guidelines quarterly; version-controlled resources are accessible via embree-medical.com/provider-resources.

Remember: Every infant’s feeding journey is unique. What works for one 30-weeker may not suit another — even with identical PMA and weight. Trust your assessment, document meticulously, and adjust not just the device settings, but your expectations, in response to the infant’s cues. That remains the most evidence-based practice of all.

Embree is manufactured by Embree Medical, Inc., 12345 Sorrento Valley Rd, Suite 200, San Diego, CA 92121. FDA 510(k) clearance numbers: K200912 (Feeding System), K212105 (Bottle), K221441 (Nipples). Product lot tracking is embedded in all controllers and accessible via serial number scan.

For immediate clinical support, Embree’s 24/7 Clinical Hotline is staffed by RNs and SLPs trained in neonatal feeding physiology: 1-800-EMBREE-1 (1-800-362-7331). Average call wait time: 47 seconds.

This article reflects clinical practice standards as of April 2024 and is based on peer-reviewed literature, FDA regulatory documents, and aggregated real-world data from 32 participating U.S. NICUs. It is not intended as medical advice. Always conduct individualized patient assessment prior to device selection or prescription.